<?xml version="1.0" encoding="UTF-8"?>
<p id="Par37">Conversely, ICU patients that could be managed with non-invasive ventilation were, respectively, 62% [
 <xref ref-type="bibr" rid="CR52">52</xref>], 56% [
 <xref ref-type="bibr" rid="CR51">51</xref>], 42% [
 <xref ref-type="bibr" rid="CR50">50</xref>], 19% [
 <xref ref-type="bibr" rid="CR49">49</xref>] and 11% [
 <xref ref-type="bibr" rid="CR48">48</xref>]. As regards NIV, data on Middle East Respiratory Syndrome (MERS) patients suggest a high failure rate [
 <xref ref-type="bibr" rid="CR53">53</xref>]. Moreover, NIV carries the risk of widespread diffusion of exhaled air and airborne viral transmission, although recent reports show that newer systems with good interface fitting might reduce this risk [
 <xref ref-type="bibr" rid="CR54">54</xref>, 
 <xref ref-type="bibr" rid="CR55">55</xref>]. It is recommended that patients receiving a trial of NIV remain in a monitored setting, with the possibility of rapid ETI in case of acute deterioration or lack of improvement [
 <xref ref-type="bibr" rid="CR7">7</xref>].
</p>
